Hormone therapy and selective estrogen receptor modulators for prevention of coronary heart disease in postmenopausal women: Estrogen replacement from the cardiologist's perspective

Cardiology in Review

Volumn 12, Issue 6, 2004, Pages 287-298

  Mobasseri, Sara ^a   Liebson, Philip R ^a   Klein, Lloyd W ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Coronary heart disease risk; Hormone therapy; Selective estrogen receptor modulators

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEDROXYPROGESTERONE ACETATE; PROGESTERONE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

BLOOD VESSEL REACTIVITY; BREAST CANCER; CANCER RISK; CARDIOVASCULAR RISK; CLINICAL TRIAL; COLORECTAL CANCER; CORONARY RISK; DRUG EFFICACY; DRUG SAFETY; ENDOMETRIUM CANCER; ESTROGEN THERAPY; HUMAN; INSULIN SENSITIVITY; ISCHEMIC HEART DISEASE; LIPID METABOLISM; OVARY CANCER; POSTMENOPAUSE; PRACTICE GUIDELINE; PRIMARY PREVENTION; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SECONDARY PREVENTION; SYSTEMATIC REVIEW; THROMBOEMBOLISM;

CORONARY DISEASE; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MIDDLE AGED; POSTMENOPAUSE; RALOXIFENE; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SOCIOECONOMIC FACTORS;

EID: 7044230010     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.crd.0000131189.50041.d1     Document Type: Review

References (117)

1. Writing Group for the Women's Health Initiative. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
2. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in post-menopausal women. JAMA. 1998;280:605-613.
3. Mosca L, Collins P, Herrington DM, et al. Hormone replacement therapy and cardiovascular disease: a statement for healthcare professionals for the American Heart Association. Circulation. 2001;104:499-503.
4. Laine C. Postmenopausal hormone replacement therapy: how could we have been so wrong? Ann Intern Med. 2002;137:290.
5. Miller AP, Oparil S. Secondary prevention of coronary heart disease in women: a call to action. Ann Intern Med. 2003;138:150-151.
6. Herrington DM. Hormone replacement therapy and heart disease. Replacing dogma with data. Circulation. 2003;107:2-4.
7. Grodstein F, Clarkson TB, Manson JE. Understanding the divergent data on postmenopausal hormone therapy. N Engl J Med. 2003;348:645-650.
8. Davidson MH, Testolin LM, Makik C, et al. A comparison estrogen replacement, pravastatin, and combined treatment for the management of hypercholesterolemia in postmenopausal women. Arch Intern Med. 1997;157:1186-1192.
9. Colditz GA, Willett WC, Stampher MJ, et al. Menopause and the risk of coronary heart disease in women. N Engl J Med. 1987;316:1105-1110.
10. Welty FK. Who should receive hormone replacement therapy? J Thromb Thrombol. 1996;3:13-21.
11. Campos H, McNamara JR, Wilson PWF, et al. Differences in low density lipoprotein subfractions and apolipoproteins in premenopausal and postmenopausal women. J Clin Endocrinol Metab. 1988;67:30-35.
12. Stevenson JC, Crook D, Godsland IF. Influence of age and menopause on serum lipids and lipoproteins in healthy women. Atherosclerosis. 1993;98:83-90.
13. Campos H, Blijlevens E, McNamara JR, et al. LDL particle size distribution: results from the Framingham offspring study. Arterioscler Thromb. 1992;12:1410-1419.
14. Manolio TA, Pearson TA, Wenger NK, et al. Cholesterol and heart disease in older persons and women: review of an NHLBI workshop. Ann Epidemiol. 1992;2:161-176.
15. Walsh JM, Grady D. Treatment of hyperlipidemia in women. JAMA. 1995;274:1152-1158.
16. Kannel WB, Wilson PW. Risk factors that attenuate the female coronary risk advantage. Arch Intern Med. 1995;155:57-61.
17. La Rosa JC. Triglycerides and coronary risk in women and the elderly. Arch Intern Med. 1997;157:961-968.
18. Rath M, Niendorf A, Reblin T, et al. Detection and quantification of lipoprotein (a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis. 1989;9:570-592.
19. Maher VMG, Brown BG, Marcovina SM, et al. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). JAMA. 1995;274:1771-1774.
20. Niendorf A, Rath M, Wolf K, et al. Morphologic detection and quantification of lipoprotein (a) deposition in atheromatous lesions of human aorta and coronary arteries. Virchows Arch A Pathol Anat. 1990;417:105-111.
21. Bostom AG, Gagnon DR, Cupples A, et al. A prospective investigation of elevated lipoprotein (a) detected by electrophoresis and cardiovascular disease in women: the Framingham Heart Study. Circulation. 1994;90:1688-1695.
22. Grodstein F, Stampher M. The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women. Prog Cardiovasc Dis. 1995;38:199-210.
23. Stampfer MJ, Coldtiz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiological evidence. Prev Med. 1991;20:47-63.
24. Stampfer MH, Willet WC, Colditz GA, et al. A prospective study of postmenopausal estrogen therapy coronary heart disease. N Engl J Med. 1985;313:1044-1049.
25. Knopp RH, Zhu X, Bonet B. Effect of estrogens on lipoprotein metabolism and cardiovascular disease in women. Atherosclerosis. 1994:S83-S91.
26. Kim CJ, Jang HC, Cho DH. Effects of hormone replacement therapy on lipoproteins and lipids in postmenopausal women. Arterioscler Thromb. 1994;14:275-281.
27. The Writing Group for the PEPI Trial. Effects of estrogen/progestin regimens on heart disease in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. JAMA. 1995;273:199-208.
28. Kim CJ, Ryu WS, Kwak JW, et al. Changes in Lp(a) lipoprotein and lipid levels after cessation of female sex hormone production and estrogen replacement therapy. Arch Intern Med. 1996;156:500-594.
29. Espeland MA, Marcovina SM, Miller V, et al. Effect of postmenopausal hormone therapy on lipoprotein(a) concentration. Circulation. 1998;97:979-986.
30. Herrington DM, Howard TD, Hawkins GA, et al. Estrogen receptor polymorphisms and estrogen replacement on high-density lipoprotein cholesterol in women with coronary disease. N Engl J Med. 2002;346:967-974.
31. Massafra C, Buonocore G, Gioia D, et al. Effects of estradiol and medroxyprogesterone-acetate treatment on erythrocyte antioxidant enzyme activities and malondialdehyde plasma levels in amenorrheic women. J Clin Endocrinol Metab. 1997;82:173-175.
32. Bar J, Tepper R, Fuchs J, et al. The effect of estrogen replacement therapy on platelet aggregation and adenosine triphosphate release in postmenopausal women. Obstet Gynecol. 1993;81:261-264.
33. Williams AK, Adams MR, Klopfenstein HS. Estrogen modulates responses of atherosclerotic coronary arteries. Circulation. 1990;81:1680-1687.
34. Kim YD, Chen B, Beauregard J, et al. 17 Beta-estradiol prevents dysfunction of canine coronary endothelium and myocardium and myocardium and reperfusion arrhythmias after brief ischemia/reperfusion. Circulation. 1996;94:2901-2908.
35. Skafar DF, Rui XU, Morales J, et al. Clinical review 91: female sex hormones and cardiovascular disease in women. J Clin Endocrinol Metab. 1997;82:3913-3918.
36. Holm P, Korsgaard N, Shalmi M, et al. Significant reduction of the antiatherogenic effect of estrogen by long-term inhibition of nitric oxide synthesis in cholesterol-clamped rabbits. J Clin Invest. 1997;100:821-828.
37. Chen SJ, Li H, Durand J, et al. Estrogen reduces myointimal proliferation after balloon injury of rat carotid artery. Circulation. 1996;1993:577-584.
38. Nabulsi AA, Folsom AR, White A, et al. Association of hormone-replacement therapy with various cardiovascular risk factors in women. Atherosclerosis Risk in Communities Study investigators. N Engl J Med. 1993;328:1069-1075.
39. Koh KK, Mincemoyer R, Bui MN, et al. Effects of hormone replacement therapy on fibrinolysis in postmenopausal women. N Engl J Med. 1997;336:683-690.
40. Salomaa V, Rasi V, Kekkanen J, et al. Association of hormone replacement therapy with hemostatic and other cardiovascular risk factors: the FINRISK hemostasis study. Arterioscler Thromb Vasc Biol. 1995;15:1549-1555.
41. Sullivan JM, Vander Zwaag R, Hughes JP, et al. Estrogen replacement and coronary artery disease: effect on survival in postmenopausal women. Arch Intern Med. 1990;150:2557-2562.
42. Nabulsi AA, Folsom AR, Szklo M, et al. No association of menopause and hormone replacement therapy with carotid artery intima-media thickness. Circulation. 1996;94:1857-1863.
43. Hodis NH, Mack WJ, Lobo RA, et al. Estrogen in the prevention of atherosclerosis. Ann Intern Med. 2001;135:939-953.
44. Jiang C, Sarrel PM, Lindsay DC, et al. Endothelium-independent relations of rabbit coronary artery by 17 β-oestradiol in vitro. Br J Pharmacol. 1991;104:1033-1037.
45. Jiang C, Sarrel PM, Lindsay DC, et al. Acute effect of 17 β-oestradiol on rabbit coronary artery contractile responses to endothelium-1. Am J Physiol. 1992;263:H271-H275.
46. 2+ in guinea-pig isolated cardiac myocytes. Br J Pharmacol. 1992;106:739-745.
47. Williams AK, Adams MR, Herrington DM, et al. Short-term administration of estrogen and vascular responses of atherosclerotic coronary arteries. J Am Coll Cardiol. 1992;20:452-457.
48. Collins P, Rosano G, Sarrel P, et al. 17 beta-Estradiol attenuates acetylcholine-induced coronary arterial constriction in women but not in men with coronary heart disease. Circulation. 1995;92:24-30.
49. Reis SE, Gloth ST, Blumenthal RS, et al. Ethinyl estradiol acutely attenuates abnormal coronary vasomotor responses to acetylcholine in post-menopausal women. Circulation. 1994;89:52-60.
50. Charney P. Coronary artery disease in women: the menstrual cycle and other risk factors. Ann Intern Med. 2001;135:1002-1004.
51. Lloyd GW, Patel NR, McGing E, et al. Does angina vary with the menstrual cycle in women with premenopausal coronary artery disease? Heart. 2000;84:189-192.
52. Krejza J, Mariak Z, Huba M, et al. Effect of endogenous estrogen on blood flow through carotid arteries. Stroke. 2001;32:30-36.
53. Kawano H, Motoyama T, Ohgushi M, et al. Menstrual cyclic variation of myocardial ischemia in premenopausal women with variant angina. Ann Intern Med. 2001;135:977-981.
54. Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopausal estrogen therapy and cardiovascular disease: 10 year follow-up from the Nurses' Health Study. N Engl J Med. 1991;325:756-762.
55. Kriz-Silverstein D, Barrett-Connor E. Long-term postmenopausal hormone use, obesity, and fat distribution in older women. JAMA. 1996;275:46-49.
56. Haarbo J, Marslew U, Gotfredsen A, et al. Postmenopausal hormone replacement therapy prevents central distribution of body fat after menopause. Metabolism. 1991;40:1323-1326.
57. Lobo RA, Pickar JH, Wild RA, et al. Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women. Obstet Gynecol. 1994;84:987-995.
58. Andersson B, Mattsson LA, Hahn L, et al. Estrogen replacement therapy decreases hyperandrogenicity and improves glucose homeostasis and plasma lipids in postmenopausal women with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1997;82:638-643.
59. Godsland IF, Crook D, Simpson R, et al. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N Engl J Med. 1990;323:1375-1381.
60. Williams JK, Honore EK, Washburn SA, et al. Effects of hormone replacement therapy on reactivity of atherosclerotic coronary arteries in cynomolgus monkeys. J Am Coll Cardiol. 1994;24:1757-1761.
61. Ridker PM, Buring JE, Shih J, et al. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation. 1998;98:731-733.
62. Wenger NK, Speroff L, Packard B. Cardiovascular disease in women. Circulation. 1993;88:1999-2009.
63. Barrett-Connor E, Grady D. Hormone replacement therapy: is it useful for coronary prevention? Cardiol Clin. 1998;16:17-25.
64. Barrett-Connor E, Grady D. Hormone replacement therapy and heart disease and other considerations. Annu Rev Public Health. 1998;19:55-72.
65. Humphrey LL, Chan BKS, Sox HC. Postmenopausal therapy and primary prevention of cardiovascular disease. Ann Intern Med. 2002;137:273-284.
66. Nelson HD, Humprhey LL, Nygren P, et al. Postmenopausal hormone replacement therapy: scientific review. JAMA. 2002;288:872-881.
67. Fletcher SW, Graham CA. Failure of estrogen plus progestin therapy for prevention. JAMA. 2002;288:366-368.
68. Bush TL, Barrett-Connor E, Cowan LD, et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation. 1987;75:1102-1109.
69. Sullivan JM, EI-Zeky F, Vander Zwaag R, et al. Estrogen replacement therapy after coronary artery bypass surgery: effect on survival [abstract]. J Am Coll Cardiol. 1994;23:7.
70. Sullivan JM, Zwaag RV, Lamp GF, et al. Postmenopausal estrogen use and coronary atherosclerosis. Ann Intern Med. 1988;108:358-363.
71. Kim SC, O'Keefe JH Jr, Ligon RW, et al. Estrogen improves long-term outcome after coronary angioplasty [abstract]. Circulation. 1995;92(suppl I):I-674.
72. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen Progestin Replacement Study Follow-up (HERS-II). JAMA2002;288:49-57.
73. Petitti DB. Hormone replacement therapy for prevention. More evidence, more pessimism. JAMA 2002;288:99-101.
74. Furberg CD, Vittinghoff E, Davidson M, et al. Subgroup interactions in the Heart and Estrogen/Progestin Replacement Study: lesson learned. Circulation. 2002;105:917-922.
75. Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary artery atherosclerosis. N Engl J Med. 2000;343:522-529.
76. Nabel EG. Coronary heart disease in women: an ounce of prevention. N Engl J Med. 2000;343:572-574.
77. Waters DD, Alderman EL, Hsia J, et al. Effect of hormone replacement therapy and antioxidant vitamin supplement on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. JAMA. 2002;288:2432-2440.
78. Angerer P, Stork S, Kothny W, et al. Effects of oral post-menopausal hormone replacement on progression of atherosclerosis: a randomized controlled trial. Arterioscler Thromb Vasc Biol. 2001;21:262-268.
79. Angerer P, Stork S, Kothny W, et al. Effect of postmenopausal hormone replacement on atherosclerosis in femoral arteries. Maturitas. 2002;41:51-60.
80. Paganini-Hill A, Ross RK, Henderson BE. Postmenopausal estrogen treatment and stroke: a prospective study. BMJ. 1988;297:519-522.
81. Finucane FF, Madens JH, Bush TL, et al. Decreased risk of stroke among post-menopausal hormone users: results from a national cohort. Arch Intern Med. 1993;152:79-90.
82. Falkeborn M, Persson I, Terent A, et al. Hormone replacement therapy and the risk of stroke: follow-up of a population based cohort in Sweden. Arch Intern Med. 1993;153:1201-1209.
83. Viscoli CM, Brass LM, Kernan WN, et al. A clinical trial of estrogen replacement therapy after ischemic stroke. N Engl J Med. 2001;345:1243-1249.
84. Schulman ST, Thiemann DR, Ouyang P, et al. Effects of acute hormone therapy on recurrent ischemia in postmenopausal women with unstable angina. J Am Coll Cardiol. 2002;39:231-237.
85. Waters DD. Estrogen therapy for unstable angina [editorial]. J Am Coll Cardiol. 2002;39:238-240.
86. Ferrara A, Quesenberry CP, Karter AJ, et al. Current use of unopposed estrogen and progestin and risk of acute myocardial infarction among women with diabetes. The Northern California Kaiser Permanente Diabetes Registry, 1995-1998. Circulation. 2003;107:43-48.
87. Collaborative group on hormonal factors in breast cancer. Breast cancer and hormone replacement therapy: collaborative re-analysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet. 1997;350:1047-1059.
88. Dixon JM. Hormone replacement therapy and the breast. BMJ. 2001;323:1381-1382.
89. Hulley S, Furberg C, Barrett-Connor E, et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/Progestin Replacement Study Follow-up (HERS-II). JAMA. 2002;22:58-66.
90. Lacey JV, Mink PJ, Lubin JH, et al. Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA. 2002;288:334-341.
91. Noller KL. Estrogen replacement therapy and risk of ovarian cancer. JAMA. 2002;288:368-369.
92. Henderson VW, Paganini-Hill A, Miller BL, et al. Estrogen for Alzheimer's disease in women: randomized, double-blind, placebo-controlled trial. Neurology. 2000;54:295-301.
93. Mulnard RA, Cotman CW, Kawas C, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer's disease: a randomized controlled trial. JAMA 2000;283:1007-1015.
94. MacLennan A, Lester S, Moore V. Oral estrogen replacement therapy versus placebo for hot flashes: a systematic review. Climacteric. 2001;4:58-74.
95. Loprinzi CL, Michalak JC, Quella SK, et al. Megestrol acetate for the prevention of hot flashes. N Engl J Med. 1994;331:347-352.
96. Loprinzi CL, Kugler JW, Sloan JA, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomized controlled trial. Lancet. 2000;356:2059-2063.
97. Stearns V, Isaacs C, Rowland J, et al. A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors. Ann Oncol. 2000;11:17-22.
98. Pandya KJ, Raubertaus RF, Flynn PJ, et al. Oral clonidine in post-menopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a University of Rochester Cancer Center Community Clinical Oncology Program Study. Ann Intern Med. 2000;132:78-93.
99. Torgerson DJ, Bell-Syer SEM. Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. JAMA. 2001;285:2891-2897.
100. Alexander KP, Newby K, Hellkamp AS, et al. Initiation of hormone replacement infarction is associated with more cardiac events during follow-up. J Am Coll Cardiol. 2001;38:1-10.
101. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. JAMA. 1999;282:1344-1352.
102. Black DM, Cummings SR, Karpf DB, et al. Randomized trial of the effect of alendronate on risk fracture in women with existing vertebral fractures. Lancet. 1996;348:1535-1541.
103. McClurg MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med. 2001;244:333-340.
104. McDonald CC, Alexander FE, Whyte BW, et al. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomized trial. BMJ. 1995;311:977-980.
105. Costantino JP, Kuller LH, Ives DG, et al. Coronary heart disease mortality and adjuvant tamoxifen therapy. J Natl Cancer Inst. 1997;89:776-782.
106. McDonald CC, Stewart HJ. Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee. BMJ. 1991;303:435-437.
107. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Early Breast Cancer Trialists' Collaborative Group. Lancet. 1998;351:1451-1467.
108. Malfetano JH. Tamoxifen: associated endometrial carcinoma in post-menopausal breast and endometrial cancer. Gynecol Oncol. 1990;30:82-84.
109. Kauffman RF, Bensch WR, Roudebush RE, et al. Hypocholesterolemic activity of raloxifene (LY139481): pharmacological characterization as a selective estrogen receptor modular. J Pharmacol Exp Ther. 1997;280:146-153.
110. Rahimian R, Laher I, Dube G, et al. Estrogen and selective estrogen receptor modulator LY117018 enhance release of nitric oxide in rat aorta. J Pharmacol Exp Ther. 1997;283:116-122.
111. Walsh BW, Kuller LH, Wild RA, et al. The effect of raloxifene on markers of cardiovascular risk in healthy, post-menopausal women. JAMA. 1998;279:1445-1451.
112. Jordan VC, Glusman JE, Eckert S, et al. Incident primary breast cancers are reduced by raloxifene: integrated data from multicenter, double-blinded, randomized trials in 12,000 postmenopausal women [abstract]. Proc Am Soc Oncol. 1998;17:122a.
113. Evista [package insert]. Indianapolis, IN: Eli Lilly and Company; 1998.
114. Glusman J, Lu Y, Huster W, et al. Raloxifene effects on climacteric symptoms compared with hormone or estrogen replacement therapy (HRT or ERT) [abstract]. In: The North American Menopause Society 8th Annual Meeting Program. Boston, MA. September 4-6, 1997:65:
115. Draper MW, Flowers DE, Huster WJ, et al. A controlled trial of raloxifene (LY139481) HCL: Impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Res. 1996;11:835-842.
116. Delmas P, Bjarnson NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in post-menopausal women. N Engl J Med. 1997;337:1641-1647.
117. Barrett-Connor E, Grady D, Sashegi A, et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women. Four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) Randomized Trial. JAMA. 2002;287:847-857.